Bayer shares plunge by more than 20% after trial of potential blockbuster drug halted

Bayer lost a fifth of its market value at one point Monday, after the German pharmaceutical and agricultural group said it had ended a late-stage test for the anti-thrombotic drug asundexian due to a lack of efficacy.